121 related articles for article (PubMed ID: 12047964)
1. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial.
Maughan TS; James RD; Kerr DJ; Ledermann JA; McArdle C; Seymour MT; Cohen D; Hopwood P; Johnston C; Stephens RJ;
Lancet; 2002 May; 359(9317):1555-63. PubMed ID: 12047964
[TBL] [Abstract][Full Text] [Related]
2. Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer.
Hale JP; Cohen DR; Maughan TS; Stephens RJ
Br J Cancer; 2002 Jun; 86(11):1684-90. PubMed ID: 12087450
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
4. A patient preference study comparing raltitrexed ('Tomudex') and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effects and administration attributes.
Young A; Topham C; Moore J; Turner J; Wardle J; Downes M; Evans V; Kay S
Eur J Cancer Care (Engl); 1999 Sep; 8(3):154-61. PubMed ID: 10763646
[TBL] [Abstract][Full Text] [Related]
5. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
6. Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas.
Gebbia V; Verderame F; Ferraù F; Bordonaro R; Callari A; Caruso M; Tirrito ML; Valenza R; Cicero G; Borsellino N; Tralongo P
Ann Oncol; 2006 Jun; 17 Suppl 7():vii60-5. PubMed ID: 16760296
[TBL] [Abstract][Full Text] [Related]
7. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.
Maughan TS; James RD; Kerr DJ; Ledermann JA; Seymour MT; Topham C; McArdle C; Cain D; Stephens RJ;
Lancet; 2003 Feb; 361(9356):457-64. PubMed ID: 12583944
[TBL] [Abstract][Full Text] [Related]
8. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
[TBL] [Abstract][Full Text] [Related]
9. Mature results from three large controlled studies with raltitrexed ('Tomudex').
Cunningham D
Br J Cancer; 1998; 77 Suppl 2(Suppl 2):15-21. PubMed ID: 9579851
[TBL] [Abstract][Full Text] [Related]
10. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial.
Kerr DJ; McArdle CS; Ledermann J; Taylor I; Sherlock DJ; Schlag PM; Buckels J; Mayer D; Cain D; Stephens RJ; ;
Lancet; 2003 Feb; 361(9355):368-73. PubMed ID: 12573372
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.
Popescu RA; Norman A; Ross PJ; Parikh B; Cunningham D
J Clin Oncol; 1999 Aug; 17(8):2412-8. PubMed ID: 10561304
[TBL] [Abstract][Full Text] [Related]
12. Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
Guglielmi A; Aschele C; Grossi F; Tixi L; Sobrero A
Cytotechnology; 1996; 19(3):215-9. PubMed ID: 8862009
[TBL] [Abstract][Full Text] [Related]
13. Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.
Ducreux M; Bouche O; Pignon JP; Mousseau M; Raoul JL; Cassan P; Leduc B; Berger C; Dunant A; Fournet J; Bedenne L;
Oncology; 2006; 70(3):222-30. PubMed ID: 16816536
[TBL] [Abstract][Full Text] [Related]
14. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II study of fractionated bimonthly oxaliplatin with leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer, pre-treated with chemotherapy.
Recchia F; Rea S; Nuzzo A; Lalli A; Di Lullo L; De Filippis S; Saggio G; Di Blasio A; Massa E; Mantovani G
Oncol Rep; 2003; 10(1):65-9. PubMed ID: 12469146
[TBL] [Abstract][Full Text] [Related]
16. Toxicity analysis of the 5-day bolus 5-fluorouracil/folinic acid regimen for the treatment of colorectal carcinoma from 2 randomized controlled trials: a concern about dose.
Vincent M; Ho C; Tomiak A; Winquist E; Whiston F; Stitt L
Clin Colorectal Cancer; 2002 Aug; 2(2):111-8. PubMed ID: 12453326
[TBL] [Abstract][Full Text] [Related]
17. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid.
Sculpher M; Palmer MK; Heyes A
Pharmacoeconomics; 2000 Apr; 17(4):361-70. PubMed ID: 10947491
[TBL] [Abstract][Full Text] [Related]
18. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.
Scheithauer W; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger W; Gedlicka C; Schüll B; Brugger S; Schneeweiss B; Lang F; Lenauer A; Depisch D
J Clin Oncol; 2002 Jan; 20(1):165-72. PubMed ID: 11773166
[TBL] [Abstract][Full Text] [Related]
19. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
Poon MA; O'Connell MJ; Moertel CG; Wieand HS; Cullinan SA; Everson LK; Krook JE; Mailliard JA; Laurie JA; Tschetter LK
J Clin Oncol; 1989 Oct; 7(10):1407-18. PubMed ID: 2476530
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.
Borget I; Aupérin A; Pignon JP; Abbas M; Bouché O; Mousseau M; Raoul JL; Bedenne L; Cassan P; Clavero-Fabri MC; Stremsdoerfer N; Nasca S; Queuniet AM; Ducreux M;
Oncology; 2006; 71(1-2):40-8. PubMed ID: 17344670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
